DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for congenital mesoblastic nephroma — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCongenital mesoblastic nephroma maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for congenital mesoblastic nephroma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
neurotrophic receptor tyrosine kinase 3 (NTRK3) — NTRK3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-aminophenyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6KZD · 1.708 Å · ligand 3-[2-[6-(4-aminophenyl)imidazo[1,2-a]pyrazin-3-yl]ethynyl]-2-methyl-~{N}-[3-(4-methylpiperazin-1-yl)-5-propan-2-yl-phenyl]benzamide (DZ6). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Nepal Medical Association · 2023 · 4 citations · open access
Congenital Mesoblastic Nephroma: A Case Report
AbstractCongenital mesoblastic nephromas are rare renal tumours that are encountered in paediatric age group. A term female neonate at the end of first week of life presented with bilateral lower limb swelling. On radiological evaluation, ultrasonography revealed an intra-abdominal mass which was managed with radical nephroureterectomy. Histopathological examination confirmed a diagnosis of congenital mesoblastic nephroma of mixed subtype. Keywords: case reports; congenital mesoblastic nephroma; kidney neoplasms; nephrectomy.
Journal of diagnostic medical sonography · 2009 · 1 citations · open access
Congenital Mesoblastic Nephroma
AbstractCongenital mesoblastic nephroma is a rare renal tumor of early infancy with a favorable outcome after complete surgical removal. It consists of a heterogeneous group of spindle cell tumors. Early and accurate prenatal diagnosis of the renal tumor may improve the outcome of affected pregnancies by implementing the best strategy for prenatal management and delivery. But detection of congenital mesoblastic nephroma in a fetus is rare. To the authors' knowledge, there are fewer than 30 reports of a prenatal diagnosis of a mesoblastic nephroma in the literature. This case describes the prenatal sonographic diagnosis of cellular congenital mesoblastic nephroma.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
